Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/0284186X.2011.592149 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nanostructured lipid carriers based mRNA vaccine leads to a T cell-inflamed tumour microenvironment favourable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumour model.
EBioMedicine
January 2025
Univ. Grenoble Alpes, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR, Grenoble, 5309, France.
Background: mRNA-based cancer vaccines show promise in triggering antitumour immune responses. To combine them with existing immunotherapies, the intratumoral immune microenvironment needs to be deeply characterised. Here, we test nanostructured lipid carriers (NLCs), the so-called Lipidots®, for delivering unmodified mRNA encoding Ovalbumin (OVA) antigen to elicit specific antitumour responses.
View Article and Find Full Text PDFEfficacy and Safety of Re-Challenging PD-1 Inhibitors in Second-Line Treatment in Metastatic Nasopharyngeal Carcinoma Previously Treated with Chemotherapy and PD-1 Inhibitors.
Cancer Manag Res
July 2024
Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China.
Background: We aim to evaluate the efficacy and safety of anti-PD1 rechallenge in combination with chemotherapy in patients with metastatic nasopharyngeal carcinoma (mNPC) who have progressed on prior anti-PD1 therapy.
Patients And Methods: We enrolled patients with mNPC who received chemotherapy combined with PD-1 immune-checkpoint inhibitors (ICIs) or chemotherapy alone after prior progression of anti-PD1 therapy. The primary endpoint was progress-free survival (PFS), and the secondary endpoints included overall survival (OS), disease control rate (DCR) and objective response rate (ORR).
Resiquimod-loaded cationic liposomes cure mice with peritoneal carcinomatosis and induce specific anti-tumor immunity.
J Control Release
August 2024
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada. Electronic address:
Article Synopsis
- Peritoneal carcinomatosis (PC) has a high recurrence and mortality rate after treatments due to incomplete cancer removal, prompting the development of new therapies.
- Two cationic liposomal formulations were created to deliver the immune-activating agent resiquimod (R848) directly to the peritoneum, significantly increasing its retention and enhancing immune responses without raising levels in the bloodstream.
- In mouse models of colon cancer, these formulations combined with oxaliplatin improved the infiltration of immune cells and achieved a 60-70% cure rate, demonstrating strong antitumor immunity and long-term immune memory against the specific cancer type.
Therapeutic effects of orally administration of viable and inactivated probiotic strains against murine urinary tract infection.
J Food Drug Anal
December 2023
Department of Veterinary Medicine, College of Veterinary Medicine, National Chung Hsing University, Taichung 40249, Taiwan.
Article Synopsis
- Urinary tract infections (UTIs) are common bacterial infections that can lead to serious health issues, and specific probiotic strains are suggested for their management and mitigating antibiotic resistance.
- Heat-killed probiotics, especially those producing lactoferrin (LF), show promise against UTIs, although the effectiveness of these inactivated probiotics is still being investigated.
- A study tested the antibacterial properties of heat-killed LF-expressing probiotics and found them to be more effective than natural probiotics in lab tests, followed by an in vivo trial in mice to evaluate their therapeutic potential against UTIs.
Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma.
Clin Lymphoma Myeloma Leuk
February 2024
The University of Texas MD Anderson Cancer Center, Houston, TX.
Background: No established standard of care exists for relapsed/refractory (RR) follicular lymphoma (FL) after ≥2 prior therapies. We conducted indirect treatment comparisons (ITCs) to compare the efficacy and tolerability of mosunetuzumab with those of available treatments used in this setting.
Methods: A systematic literature review (SLR) and subsequent feasibility assessments were conducted to identify the most suitable comparator studies in terms of design, available endpoints and populations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!